Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers

Investigator: Eric Bernicker, MD

Study Coordinator: Meena Medepalli

Status: Enrolling

ClinicalTrials.gov Number: NCT02595944

Phone: 713.441.4203

IRB Number: Pro00016419

Description

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.
More to Explore